Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI.
Crit Care Med. 2018 Feb;46(2):e158-e165. doi: 10.1097/CCM.0000000000002878.
Acute renal replacement therapy in patients with sepsis has increased dramatically with substantial costs. However, the extent of variability in use across hospitals-and whether greater use is associated with better outcomes-is unknown.
Retrospective cohort study.
Nationwide Inpatient Sample in 2011.
Eighteen years old and older with sepsis and acute kidney injury admitted to hospitals sampled by the Nationwide Inpatient Sample in 2011.
We estimated the risk- and reliability-adjusted rate of acute renal replacement therapy use for patients with sepsis and acute kidney injury at each hospital. We examined the association between hospital-specific renal replacement therapy rate and in-hospital mortality and hospital costs after adjusting for patient and hospital characteristics.
We identified 293,899 hospitalizations with sepsis and acute kidney injury at 440 hospitals, of which 6.4% (n = 18,885) received renal replacement therapy. After risk and reliability adjustment, the median hospital renal replacement therapy rate for patients with sepsis and acute kidney injury was 3.6% (interquartile range, 2.9-4.5%). However, hospitals in the top quintile of renal replacement therapy use had rates ranging from 4.8% to 13.4%. There was no significant association between hospital-specific renal replacement therapy rate and in-hospital mortality (odds ratio per 1% increase in renal replacement therapy rate: 1.03; 95% CI, 0.99-1.07; p = 0.10). Hospital costs were significantly higher with increasing renal replacement therapy rates (absolute cost increase per 1% increase in renal replacement therapy rate: $1,316; 95% CI, $157-$2,475; p = 0.03).
Use of renal replacement therapy in sepsis varied widely among nationally sampled hospitals without associated differences in mortality. Improving renal replacement standards for the initiation of therapy for sepsis may reduce healthcare costs without increasing mortality.
脓毒症患者的急性肾脏替代疗法(acute renal replacement therapy,ARRT)的应用显著增加,费用也大幅上升。然而,目前尚不清楚各医院之间 ARRT 使用的差异程度,以及这种差异是否与更好的预后相关。
回顾性队列研究。
2011 年全国住院患者样本。
18 岁及以上因脓毒症合并急性肾损伤而入院的患者,这些患者均来自 2011 年全国住院患者样本中抽取的医院。
我们估计了每家医院的脓毒症合并急性肾损伤患者接受 ARRT 的风险和可靠性调整后的使用率。我们在调整了患者和医院特征后,检验了医院特定的肾脏替代治疗率与住院死亡率和医院成本之间的关系。
我们在 440 家医院中确定了 293899 例脓毒症合并急性肾损伤的住院患者,其中 6.4%(n=18885)接受了肾脏替代治疗。在风险和可靠性调整后,脓毒症合并急性肾损伤患者的医院肾脏替代治疗率中位数为 3.6%(四分位距,2.9%-4.5%)。然而,肾脏替代治疗使用率最高的前 20%的医院的治疗率范围为 4.8%-13.4%。医院特定的肾脏替代治疗率与住院死亡率之间无显著关联(每增加 1%肾脏替代治疗率的比值比:1.03;95%置信区间,0.99-1.07;p=0.10)。随着肾脏替代治疗率的增加,医院的成本显著增加(每增加 1%肾脏替代治疗率的绝对成本增加:1316 美元;95%置信区间,157-2475 美元;p=0.03)。
在全国抽样的医院中,肾脏替代疗法在脓毒症中的应用差异很大,死亡率无差异。改善脓毒症起始治疗的肾脏替代治疗标准可能会降低医疗成本,而不会增加死亡率。